1st Counsel – Lifestyle
Author:
Tris Pharma, Inc.
Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer
May 5, 2026
Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix
April 8, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
March 6, 2026